Fed. Circ. Wants Redo For IP Suit Over Allergan Antipsychotic
The Federal Circuit on Thursday told a Delaware federal judge to reconsider her decision that a patent covering Allergan's antipsychotic medication Saphris is valid and that a pair of generic-drug makers...To view the full article, register now.
Already a subscriber? Click here to view full article